ClinicalTrials.gg
RecruitingNCT06680830NEULARKUpdated Oct 30, 2026

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

A Phase 2 interventional study of NEU-411 and Placebo in Parkinson Disease, Parkinson and Idiopathic Parkinson Disease, sponsored by Neuron23 Inc.. Recruiting at 72 sites in 6 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Neuron23 Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 2, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
198th of 1,257
150 · median 36
Started
2025
with 77 others
Phase 2
234 of 1,650
25 open now
Primary completion
2027-12
later than 233 of 384 live
Registered
1,483rd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 198th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 78 that started in 2025, is one of 234 in phase 2, reaches primary completion later than 233 of the 384 other live ones, and was the 1,483rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

Read the detailed description

NEU-411-PD201 is a Phase 2, randomized, placebo-controlled, proof-of-concept study and open-label extension (OLE) in participants with early Parkinson's Disease (PD) who have LRRK2-driven PD as measured by an investigational companion diagnostic genetic test (CDx). The study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NEU-411, an orally-administered, potent, selective, bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity as compared to placebo.

After participants are screened for inclusion in the randomized, placebo-controlled portion of the study, approximately 150 participants will be randomized in a 1:1 allocation to NEU-411 30 mg once per day or placebo for a 52-week treatment period with a safety follow-up visit within 2 weeks after the last treatment visit. Eligible participants may enroll in the OLE and receive treatment for an additional 26 weeks.

03

Conditions studied

  • Parkinson Disease
  • Parkinson
  • Idiopathic Parkinson Disease
  • Early Parkinson Disease (Early PD)
  • Parkinson Disease, Idiopathic

Browse trials for

Keywords

  • Early PD
  • Parkinsons
  • Parkinsons Disease
  • Idiopathic Parkinsons Disease
  • leucine-rich repeat kinase 2
  • PD
  • NEULARK
  • LRRK2
  • PARK8
  • de novo Parkinsons disease
  • Parkinson's disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 40-80 years at time of screening, inclusive
  2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)
  3. LRRK2-driven PD using the companion diagnostic genetic test (CDx)
  4. Modified Hoehn and Yahr (mH\&Y) of 1 to 2.5

Exclusion criteria

Exclusion Criteria:

  1. Secondary or atypical parkinsonian syndromes
  2. Uncontrolled diabetes mellitus with (HbA1c) >8%
  3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)

Additional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NEU-411

    Orally-administered NEU-411

    Drug: NEU-411

  • Placebo comparator
    Placebo

    Orally-administered matching placebo

    Other: Placebo

Interventions

  • DrugNEU-411

    NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity

  • OtherPlacebo

    Orally-administered matched placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Roche digital biomarker score using the Roche Parkinson's Disease application (v3.0) compared to placebo

    Time frame: From enrollment to the end of treatment at 52 weeks

  2. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo

    Time frame: From enrollment to the end of study at 54 weeks

Secondary outcomes

  1. Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Change from baseline to Week 52 in motor function/nonmotor as measured by Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Time frame: 52 weeks

07

Study locations

69 of 72 sites recruiting
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
    Recruiting
  • University of Arkansas
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Erin Hatcher · ContactEHatcher@uams.edu · 501-214-2178
    • Rohit Dhall, MD · Principal investigator
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
    Recruiting
    • Mirian Payo · Contactmirianp@neuropain.com · 559-437-9700
    • Perminder Bhatia, MD · Principal investigator
  • University of California, Irvine
    Irvine, California 92697, United States
    Recruiting
    • Rene Anguiano · Contactrenea1@hs.uci.edu · 949-824-6407
    • Sanaz Attaripour Isfahani, MD · Principal investigator
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
    • Diane Yang · ContactDDYang@mednet.ucla.edu · 310-206-3356
    • Jeff Bronstein, MD, PhD · Principal investigator
  • Esperanza Clinical
    Murrieta, California 92562, United States
    Completed

    Not enrolling at this site — choose another above.

  • Parkinson's Research Centers of America - Palo Alto
    Palo Alto, California 94301, United States
    Recruiting
  • Sutter Neuroscience Institute
    Sacramento, California 95816, United States
    Recruiting
  • University of Colorado - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
    Recruiting
  • University of Florida
    Gainesville, Florida 32608, United States
    Recruiting
  • Neurology One
    Orlando, Florida 32825, United States
    Recruiting
    • Carem Acosta · Contactcacosta@neurologyone.com · 407-674-1648
    • Ramon L Rodriguez, MD, FAAN · Principal investigator
  • USF Parkinson's & Movement Disorders Clinic
    Tampa, Florida 33613, United States
    Recruiting
    • Erica Botting · Contactericabotting@usf.edu · 813-974-8026
    • Robert Hauser, MD, MBA, FAAN · Principal investigator
  • Emory University
    Atlanta, Georgia 30329, United States
    Recruiting
  • Augusta University
    Augusta, Georgia 30912, United States
    Recruiting
    • Buff Farrow · ContactBFARROW@augusta.edu · 706-721-0619
    • John Morgan, MD, PhD · Principal investigator
  • Northwestern Medical Group, Department of Neurology
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Emily Jackson · Contactejackson9@kumc.edu · 913-588-0859
    • Rajesh Pahwa, MD · Principal investigator
  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Recruiting
    • Corisa Logan · Contactcorisa.logan@uky.edu · 859-218-5076
    • John Slevin, MD, MBA · Principal investigator
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Recruiting
  • University of Maryland
    Baltimore, Maryland 21201, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Struthers Parkinson Center
    Golden Valley, Minnesota 55427, United States
    Recruiting
  • Cleveland Clinic
    Las Vegas, Nevada 89106, United States
    Recruiting
    • Liliana Dumitrescu · ContactDUMITRL@ccf.org · 702-483-6000
    • Zoltan Mari, MD · Principal investigator
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
    Recruiting
    • Anna Tingin · Contactatingin@salud.unm.edu · 505-272-3342
    • Sarah P Richardson, MD, FAAN · Principal investigator
  • Northwell Health
    Manhasset, New York 11030, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai/Mount Sinai West
    New York, New York 10019, United States
    Recruiting
  • Columbia University
    New York, New York 10032, United States
    Recruiting
  • University of Rochester
    Rochester, New York 14618, United States
    Recruiting
  • University of North Carolina - Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • The Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
    Recruiting
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
    Recruiting
    • Emily Leonard · Contactleonarde@ohsu.edu · 503-367-4719
    • Joseph Quinn, MD · Principal investigator
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Robin Bulgarino · ContactBulgarino@musc.edu · 843-792-1115
    • Christine Cooper, MD · Principal investigator
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
    Recruiting
    • Haley Kling · Contacthaley.kling@vumc.org · 615-208-3974
    • David Charles, MD · Principal investigator
  • Neurology Consultants of Dallas PA
    Dallas, Texas 75243, United States
    Recruiting
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
    • Aneesch Martin · Contactaneesch.martin@bcm.edu · 713-798-2606
    • Arjun Tarakad, MD · Principal investigator
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Recruiting
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
    Recruiting
    • Koni Lopez · Contactk.lopez@ctncpa.org · 512-218-1222
    • Elizabeth Peckham, DO · Principal investigator
  • University of Utah Movement Division
    Salt Lake City, Utah 84108, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Lauren Miller · ContactFDK5DN@UVAHealth.org · 434-982-6599
    • Binit Shah, MD, FAAN · Principal investigator
  • EvergreenHealth
    Kirkland, Washington 98034, United States
    Recruiting
  • Inland Northwest Research
    Spokane, Washington 99202, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Shelby Schold · Contactsschold@mcw.edu · 414-955-0698
    • Karen Blindauer, MD · Principal investigator
  • Rambam Medical Center
    Haifa, 3109601, Israel
    Recruiting
    • Ilana Schlesinger, MD, Prof · Contacti_schles@rmc.gov.il · 972-4-7771495
    • Ilana Schlesinger, MD, Prof · Principal investigator
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
    Recruiting
    • Yael Mimoun · Contactyaelmi@szmc.org.il · 972-5-43184600
    • Gilad Yahalom, MD, Prof · Principal investigator
  • Sheba Medical Center
    Ramat Gan, 5262000, Israel
    Recruiting
  • Tel Aviv Medical Center
    Tel Aviv, 6423906, Israel
    Recruiting
    • Adi Ezra · Contactadil@tlvmc.gov.il · 972-3-6974912
    • Tanya Gurevich, MD, Prof · Principal investigator
  • IRCCS Ospedale San Raffaele (HSR) - Dipartimento Di Neurologia
    Milan, 20132, Italy
    Recruiting
    • Daniela Capilupo · Contactcapilupo.daniela@hsr.it · +39 0226434815
    • Massimo Filippi, MD, Prof · Principal investigator
  • Universita Degli Studi Della Campania "Luigi Vanvitelli" - Azienda Ospedaliera Universitaria
    Naples, 80138, Italy
    Recruiting
    • Teresa Del Santo · Contactdelsantoteresa@gmail.com · +39 3494026479
    • Alessandro Tessitore, MD, PhD · Principal investigator
  • Universita Degli Studi Di Padova - Azienda Ospedaliera Di Padova - Clinica Neurologica
    Padua, 35128, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Ospedaliero Di Santa Chiara
    Pisa, 56126, Italy
    Recruiting
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
    Rome, 00166, Italy
    Recruiting
  • Fondazione Policilinico Universitario A Gemelli IRCCS
    Rome, 00168, Italy
    Recruiting
  • Centrum Medyczne Neuromed
    Bydgoszcz, 85-163, Poland
    Recruiting
  • NZOZ Wielospecjalistyczna Poradnia Lekarska Synapsis Lech Szczechowski
    Katowice, 32-600, Poland
    Recruiting
    • Katarzyna Smilowska · Contactkasia.smilowska@gmail.com · +48 600282870
    • Katarzyna Smilowska, MD, PhD · Principal investigator
  • Pro Life Medica Sp. z o. o. ETA Lublin
    Lublin, 20-412, Poland
    Recruiting
    • Dominika Tomaka, MD · Contactd.tomaka@etg-network.org · +48 691485946
    • Dominika Tomaka, MD · Principal investigator
  • Insula Badania Sp. Z o.o.
    Warsaw, 02-699, Poland
    Recruiting
    • Marta Jethon · Contactjethon2@tlen.pl · +48 501035250
    • Marta Jethon, MD · Principal investigator
  • Policlinica Gipuzkoa - Centro de Investigacion Parkinson (CIP)
    San Sebastián, Donostia 20014, Spain
    Recruiting
  • Instituto de Investigacion Sanitaria Biocruces Bizkaia - Hospital Universitario Cruces
    Barakaldo, 49003, Spain
    Recruiting
    • Naiara Azcue · Contactazkue.naiara@gmail.com · +34 944881576
    • Juan Carlos Gomez Esteban, MD, PhD · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Clinic de Barcelona (Hospital Clinic i Provincial) - Barnaclinic S.A.
    Barcelona, 08036, Spain
    Recruiting
    • Alicia Garrido, Pla · Contactagarridop@clinic.cat · +34 932275785
    • Alicia Garrido, Pla · Principal investigator
  • Universidad Autonoma de Madrid (UAM) - Hospital Universitario de La Princesa
    Madrid, 28006, Spain
    Recruiting
  • Hospital Universitario HM Puerta del Sur
    Móstoles, 28938, Spain
    Recruiting
  • Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)
    Seville, 41013, Spain
    Recruiting
    • Pablo Mir, MD · Contactpmir@us.es · +34 955923039
    • Pablo Mir, MD · Principal investigator
  • St George's Hospital, University of London
    London, England SW17 0QT, United Kingdom
    Recruiting
    • Francesca Morgante, MD · Contactfmorgant@sgul.ac.uk · +44 20 8725 5403
    • Francesca Morgante, MD · Principal investigator
  • University College London Hospitals NHS Foundation Trust
    London, England WC1N 3BG, United Kingdom
    Recruiting
    • Olivia Burton · Contactolivia.burton7@NHS.net · +44 20 3448 4531
    • Huw Morris, MD, PhD · Principal investigator
  • Clinical Aging Research Unit, Newcastle University
    Newcastle upon Tyne, England NE4 5PL, United Kingdom
    Recruiting
    • Nicola Pavese, MD, PhD, FRCP, FEAN · Contactnicola.pavese@ncl.ac.uk · +44 0191 2081264
    • Nicola Pavese, MD, PhD, FRCP, FEAN · Principal investigator
  • Ninewells Hospital and Medical School - NHS Tayside
    Dundee, Scotland DD19SY, United Kingdom
    Recruiting
  • London North West University Healthcare NHS Trust - Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
    Not yet recruiting
    • Tabish Saifee, MBBS, FRCP, PhD · ContactLNWH-tr.Research@nhs.net · +44 020 3448 4252
    • Tabish Saifee, MBBS, FRCP, PhD · Principal investigator
  • Panthera Enfield
    London, EN3 4GS, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 35 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 8, 2024
StartActual
Jan 17, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Esperanza Clinical is now Completed
Oct 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Esperanza Clinical · Murrieta, United StatesContact removed h•••@esperanzaclinical.com · •••4466Contact removed (no phone or email listed)
  • Parkinson's Research Centers of America - Palo Alto · Palo Alto, United StatesContact L•••@parkinsonscenter.org · •••6690→l•••@parkinsonscenter.org · •••6690
  • EvergreenHealth · Kirkland, United StatesContact r•••@evergreenhealthcare.org · •••5370→n•••@evergreenhealthcare.org · •••5370
across 2 updates, Oct 2, 2026 – Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Parkinson's Research Centers of America - Palo Alto · Palo Alto, United StatesContact L•••@parkinsonscenter.org · •••6690→l•••@parkinsonscenter.org · •••6690
    • EvergreenHealth · Kirkland, United StatesContact r•••@evergreenhealthcare.org · •••5370→n•••@evergreenhealthcare.org · •••5370
  2. Oct 2, 2026
    Esperanza Clinical is now Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Esperanza Clinical · Murrieta, United StatesContact removed h•••@esperanzaclinical.com · •••4466Contact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06680830
Lead sponsor
Neuron23 Inc.
Collaborators
Qiagen Manchester Limited, Roche Diagnostic Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Jan 17, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Fatta B Nahab, MD, FAAN, FANA
Contact
clinicaltrials@neuron23.com
650-228-2527
Fatta B Nahab, MD, FAAN FANA
principal investigator · Neuron23 Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion